BRNS
Barinthus Biotherapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$0.76
+5.50%Aug 25, 2026, 00:00 UTC
Barinthus Biotherapeutics plc transferred its listing from NASDAQ to another exchange, as disclosed in an 8-K filing on August 24, 2026.
Aug 6, 2026, 12:00 UTC
Barinthus Biotherapeutics plc completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease.
Source:Aug 6, 2026, 12:00 UTC
Barinthus Biotherapeutics plc announced that its proposed combination with Clywedog Therapeutics Inc. is progressing towards closing.
Aug 6, 2026, 12:00 UTC
Barinthus Biotherapeutics plc reported its financial results for the quarter ended June 30, 2026.
Source: